Desmoplastic melanoma is a rare subtype of melanoma characterized by dense fibrous stroma, resistance to chemotherapy and a lack of actionable driver mutations, and is highly associated with ultraviolet light-induced DNA damage1. We analysed sixty patients with advanced desmoplastic melanoma who had been treated with antibodies to block programmed cell death 1 (PD-1) or PD-1 ligand (PD-L1). Objective tumour responses were observed in forty-two of the sixty patients (70%; 95% confidence interval 57–81%), including nineteen patients (32%) with a complete response. Whole-exome sequencing revealed a high mutational load and frequent NF1 mutations (fourteen out of seventeen cases) in these tumours. Immunohistochemistry analysis from nineteen desmoplastic melanomas and thirteen non-desmoplastic melanomas revealed a higher percentage of PD-L1-positive cells in the tumour parenchyma in desmoplastic melanomas (P = 0.04); these cells were highly associated with increased CD8 density and PD-L1 expression in the tumour invasive margin. Therefore, patients with advanced desmoplastic melanoma derive substantial clinical benefit from PD-1 or PD-L1 immune checkpoint blockade therapy, even though desmoplastic melanoma is defined by its dense desmoplastic fibrous stroma. The benefit is likely to result from the high mutational burden and a frequent pre-existing adaptive immune response limited by PD-L1 expression.

  • Subscribe to Nature for full access:



Additional access options:

Already a subscriber?  Log in  now or  Register  for online access.


  1. 1.

    et al. Exome sequencing of desmoplastic melanoma identifies recurrent NFKBIE promoter mutations and diverse activating mutations in the MAPK pathway. Nat. Genet. 47, 1194–1199 (2015)

  2. 2.

    et al. Association of pembrolizumab with tumor response and survival among patients with advanced melanoma. J. Am. Med. Assoc. 315, 1600–1609 (2016)

  3. 3.

    et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 348, 124–128 (2015)

  4. 4.

    et al. PD-1 blockade in tumors with mismatch-repair deficiency. N. Engl. J. Med. 372, 2509–2520 (2015)

  5. 5.

    et al. Genomic and transcriptomic features of response to anti-PD-1 therapy in metastatic melanoma. Cell 165, 35–44 (2016)

  6. 6.

    et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet 387, 1909–1920 (2016)

  7. 7.

    et al. Clinicopathologic predictors of survival in patients with desmoplastic melanoma. PLoS One 10, e0119716 (2015)

  8. 8.

    et al. Cutaneous desmoplastic melanoma: reappraisal of morphologic heterogeneity and prognostic factors. Am. J. Surg. Pathol. 28, 1518–1525 (2004)

  9. 9.

    Signatures of mutational processes in human cancer. Nature 500, 415–421 (2013)

  10. 10.

    et al. NF1 mutations are common in desmoplastic melanoma. Am. J. Surg. Pathol. 39, 1357–1362 (2015)

  11. 11.

    et al. Exome sequencing identifies recurrent mutations in NF1 and RASopathy genes in sun-exposed melanomas. Nat. Genet. 47, 996–1002 (2015)

  12. 12.

    et al. Whole-genome landscapes of major melanoma subtypes. Nature 545, 175–180 (2017)

  13. 13.

    et al. Genomic classification of cutaneous melanoma. Cell 161, 1681–1696 (2015)

  14. 14.

    et al. Primary resistance to PD-1 blockade mediated by JAK1/2 mutations. Cancer Discov. 7, 188–201 (2017)

  15. 15.

    et al. Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance. Sci. Transl. Med. 9, eaah3560 (2017)

  16. 16.

    et al. Genomic correlates of response to CTLA-4 blockade in metastatic melanoma. Science 350, 207–211 (2015)

  17. 17.

    et al. Mutations associated with acquired resistance to PD-1 blockade in melanoma. N. Engl. J. Med. 375, 819–829 (2016)

  18. 18.

    et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 515, 568–571 (2014)

  19. 19.

    et al. Programmed death-ligand 1 expression and response to the anti-programmed death 1 antibody pembrolizumab in melanoma. J. Clin. Oncol. 34, 4102–4109 (2016)

  20. 20.

    et al. Tumoral PD-L1 expression in desmoplastic melanoma is associated with depth of invasion, tumor-infiltrating CD8 cytotoxic lymphocytes and the mixed cytomorphological variant. Mod. Pathol. 30, 357–369 (2017)

  21. 21.

    et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin’s lymphoma. N. Engl. J. Med. 372, 311–319 (2015)

  22. 22.

    et al. Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors. Cancer Discov. 3, 1355–1363 (2013)

  23. 23.

    et al. MYC regulates the antitumor immune response through CD47 and PD-L1. Science 352, 227–231 (2016)

  24. 24.

    et al. Cdk5 disruption attenuates tumor PD-L1 expression and promotes antitumor immunity. Science 353, 399–403 (2016)

  25. 25.

    et al. Aberrant PD-L1 expression through 3′-UTR disruption in multiple cancers. Nature 534, 402–406 (2016)

  26. 26.

    The blockade of immune checkpoints in cancer immunotherapy. Nat. Rev. Cancer 12, 252–264 (2012)

  27. 27.

    et al. Targeting focal adhesion kinase renders pancreatic cancers responsive to checkpoint immunotherapy. Nat. Med. 22, 851–860 (2016)

  28. 28.

    et al. PD-1 blockade with pembrolizumab in advanced Merkel-cell carcinoma. N. Engl. J. Med. 374, 2542–2552 (2016)

  29. 29.

    et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N. Engl. J. Med. 369, 134–144 (2013)

  30. 30.

    et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet 389, 255–265 (2017)

Download references


This study was funded in part by the Grimaldi Family Fund, the Parker Institute for Cancer Immunotherapy, National Institutes of Health (NIH) grants R35 CA197633 and P01 CA168585, the Ressler Family Fund, the Samuels Family Fund and the Garcia-Corsini Family Fund (to A.R.). Z.E. was supported in part by the Moffitt Cancer Center NCI Skin SPORE (5P50CA168536) and Moffitt’s Total Cancer Care Initiative and Collaborative Data Services (P30-CA076292) for this work. J.M.Z. is part of the UCLA Medical Scientist Training Program supported by NIH training grant GM08042. S.H.-L. was supported by a Young Investigator Award and a Career Development Award from the American Society of Clinical Oncology (ASCO), a Tower Cancer Research Foundation Grant, and a Dr. Charles Coltman Fellowship Award from the Hope Foundation. We acknowledge the Translational Pathology Core Laboratory (TPCL) and R. Guo, W. Li, J. Pang and M. H. Macabali from UCLA for blood and biopsy processing, and X. Li, L. Dong, J. Yoshizawa, and J. Zhou from the UCLA Clinical Microarray Core for sequencing expertise. G.V.L. is supported by an NHMRC Fellowship and The University of Sydney Medical Foundation. R.A.S. is supported by an NHMRC Fellowship.

Author information

Author notes

    • Jeffrey A. Sosman

    Present address: Northwestern University Medical Center, Chicago, Illinois, USA.

    • Zeynep Eroglu
    • , Jesse M. Zaretsky
    •  & Siwen Hu-Lieskovan

    These authors contributed equally to this work.


  1. University of California Los Angeles, Los Angeles, California, USA

    • Zeynep Eroglu
    • , Jesse M. Zaretsky
    • , Siwen Hu-Lieskovan
    • , Bartosz Chmielowski
    • , Xiaoyan Wang
    • , I. Peter Shintaku
    • , Cody Wei
    • , Alistair J. Cochran
    •  & Antoni Ribas
  2. Moffitt Cancer Center and University of South Florida, Tampa, Florida, USA

    • Zeynep Eroglu
    • , Dae Won Kim
    •  & Jane Messina
  3. The University of Texas-MD Anderson Cancer Center, Houston, Texas, USA

    • Dae Won Kim
    •  & Wen-Jen Hwu
  4. University of California San Francisco, San Francisco, California, USA

    • Alain Algazi
  5. Vanderbilt Ingram Cancer Center, Nashville, Tennessee, USA

    • Douglas B. Johnson
    •  & Jeffrey A. Sosman
  6. Melanoma Institute Australia, Sydney, New South Wales, Australia

    • Elizabeth Liniker
    • , Matteo S. Carlino
    • , Richard A. Scolyer
    •  & Georgina V. Long
  7. Westmead Hospital, Sydney, New South Wales, Australia

    • Ben Kong
    •  & Matteo S. Carlino
  8. Memorial Sloan Kettering Cancer Center, New York, New York, USA

    • Rodrigo Munhoz
    •  & Michael A. Postow
  9. Weill Cornell Medical College, New York, New York, USA

    • Rodrigo Munhoz
    •  & Michael A. Postow
  10. Georgetown Lombardi Cancer Center, Washington DC, USA

    • Suthee Rapisuwon
  11. Parker Institute for Cancer Immunotherapy, San Francisco, California, USA

    • Pier Federico Gherardini
  12. Mayo Clinic, Jacksonville, Florida, USA

    • Richard W. Joseph
  13. The University of Sydney, Sydney, New South Wales, Australia

    • Matteo S. Carlino
    • , Richard A. Scolyer
    •  & Georgina V. Long
  14. Royal Prince Alfred Hospital, Sydney, New South Wales, Australia

    • Richard A. Scolyer
  15. Royal North Shore Hospital, Sydney, New South Wales, Australia

    • Georgina V. Long


  1. Search for Zeynep Eroglu in:

  2. Search for Jesse M. Zaretsky in:

  3. Search for Siwen Hu-Lieskovan in:

  4. Search for Dae Won Kim in:

  5. Search for Alain Algazi in:

  6. Search for Douglas B. Johnson in:

  7. Search for Elizabeth Liniker in:

  8. Search for Ben Kong in:

  9. Search for Rodrigo Munhoz in:

  10. Search for Suthee Rapisuwon in:

  11. Search for Pier Federico Gherardini in:

  12. Search for Bartosz Chmielowski in:

  13. Search for Xiaoyan Wang in:

  14. Search for I. Peter Shintaku in:

  15. Search for Cody Wei in:

  16. Search for Jeffrey A. Sosman in:

  17. Search for Richard W. Joseph in:

  18. Search for Michael A. Postow in:

  19. Search for Matteo S. Carlino in:

  20. Search for Wen-Jen Hwu in:

  21. Search for Richard A. Scolyer in:

  22. Search for Jane Messina in:

  23. Search for Alistair J. Cochran in:

  24. Search for Georgina V. Long in:

  25. Search for Antoni Ribas in:


Z.E., J.M.Z., S.H.-L. and A.R. developed the concepts. Z.E., S.H.-L, J.M.Z., and A.R. designed the experiments. Z.E., J.M.Z., S.H.-L. and A.R. interpreted the data. S.H.-L., I.P.S. and Z.E. performed IHC analyses. J.M.Z. performed genomic analyses. Z.E., A.R., B.C., D.W.K., A.A., D.B.J., E.L., B.K., R.M., S.R., J.A.S., R.J., M.A.P., M.S.C, W.-J.H., and G.V.L. clinically evaluated patients and contributed clinical data and tumour samples. R.A.S., J.M., and A.J.C. evaluated tumour samples. P.F.G. conducted the heat map analysis. X.W. performed statistical analyses. C.W. evaluated the non-DM clinical data. Z.E., J.M.Z., S.H.-L. and A.R. wrote the manuscript. S.H.-L. and A.R. supervised the project. All authors contributed to the manuscript and approved the final version.

Competing interests

The authors declare no competing financial interests.

Corresponding authors

Correspondence to Siwen Hu-Lieskovan or Antoni Ribas.

Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Extended data

Supplementary information

PDF files

  1. 1.

    Supplementary Information

    Life Sciences Reporting Summary

  2. 2.

    Life Sciences Reporting Summary


By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.